Rethinking Recurrent Ovarian Cancer – ADCs, New Taxane Combinations, Bispecifics – What Will the Future of Treatment Selection Look Like?

Explore treatment strategies for platinum-sensitive and platinum-resistant recurrent ovarian cancer, comparing optimization of outcomes with currently available therapies versus incorporation of emerging agents. Faculty will review clinical trial data, response patterns, and toxicity considerations across these approaches, providing expert perspectives on integrating established and emerging therapies to improve outcomes in recurrent ovarian cancer. This session will examine emerging treatment strategies for platinum-sensitive and platinum-resistant recurrent ovarian cancer, with a focus on antibody-drug conjugates (ADCs), novel taxane combinations, and bispecific therapies. Faculty will review early-phase and evolving clinical data supporting these agents and their mechanisms of action, as well as how these therapies may be integrated into existing treatment paradigms. Learners will gain perspective on the potential of innovative agents to expand therapeutic options in recurrent ovarian cancer.